231 related articles for article (PubMed ID: 21428920)
1. A longer and healthier life with TOR down-regulation: genetics and drugs.
Bjedov I; Partridge L
Biochem Soc Trans; 2011 Apr; 39(2):460-5. PubMed ID: 21428920
[TBL] [Abstract][Full Text] [Related]
2. Metabolic control by target of rapamycin and autophagy during ageing - a mini-review.
Markaki M; Tavernarakis N
Gerontology; 2013; 59(4):340-8. PubMed ID: 23594965
[TBL] [Abstract][Full Text] [Related]
3. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
4. Blocking the mTOR pathway: a drug discovery perspective.
Garcia-Echeverria C
Biochem Soc Trans; 2011 Apr; 39(2):451-5. PubMed ID: 21428918
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin signaling in the podocyte.
Inoki K; Huber TB
Curr Opin Nephrol Hypertens; 2012 May; 21(3):251-7. PubMed ID: 22388550
[TBL] [Abstract][Full Text] [Related]
6. Sensing nutrient and energy status by SnRK1 and TOR kinases.
Robaglia C; Thomas M; Meyer C
Curr Opin Plant Biol; 2012 Jun; 15(3):301-7. PubMed ID: 22305521
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of the ubiquitin-proteasome proteolysis system by amino acids and insulin involves the adenosine monophosphate-activated protein kinase and mammalian target of rapamycin pathways in rat hepatocytes.
Chotechuang N; Azzout-Marniche D; Bos C; Chaumontet C; Gaudichon C; Tomé D
Amino Acids; 2011 Jul; 41(2):457-68. PubMed ID: 20957397
[TBL] [Abstract][Full Text] [Related]
8. Autophagy: regulation by energy sensing.
Meijer AJ; Codogno P
Curr Biol; 2011 Mar; 21(6):R227-9. PubMed ID: 21419990
[TBL] [Abstract][Full Text] [Related]
9. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract][Full Text] [Related]
10. The role of the TOR pathway in mediating the link between nutrition and longevity.
Lushchak O; Strilbytska O; Piskovatska V; Storey KB; Koliada A; Vaiserman A
Mech Ageing Dev; 2017 Jun; 164():127-138. PubMed ID: 28315697
[TBL] [Abstract][Full Text] [Related]
11. Evolutionarily conserved regulation of TOR signalling.
Takahara T; Maeda T
J Biochem; 2013 Jul; 154(1):1-10. PubMed ID: 23698095
[TBL] [Abstract][Full Text] [Related]
12. Nutritional control of cell growth via TOR signaling in budding yeast.
Wei Y; Zheng XF
Methods Mol Biol; 2011; 759():307-19. PubMed ID: 21863495
[TBL] [Abstract][Full Text] [Related]
13. The evolution of the TOR pathway and its role in cancer.
Beauchamp EM; Platanias LC
Oncogene; 2013 Aug; 32(34):3923-32. PubMed ID: 23246968
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin additively extends lifespan in short- and long-lived lines of the nematode Caenorhabditis remanei.
Lind MI; Chen HY; Cortazar-Chinarro M; Maklakov AA
Exp Gerontol; 2017 Apr; 90():79-82. PubMed ID: 28119053
[TBL] [Abstract][Full Text] [Related]
15. Regulation of plant growth and metabolism by the TOR kinase.
Dobrenel T; Marchive C; Sormani R; Moreau M; Mozzo M; Montané MH; Menand B; Robaglia C; Meyer C
Biochem Soc Trans; 2011 Apr; 39(2):477-81. PubMed ID: 21428923
[TBL] [Abstract][Full Text] [Related]
16. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma.
Roulin D; Demartines N; Dormond O
Biochem Soc Trans; 2011 Apr; 39(2):492-4. PubMed ID: 21428926
[TBL] [Abstract][Full Text] [Related]
17. Are invertebrates relevant models in ageing research? Focus on the effects of rapamycin on TOR.
Erdogan CS; Hansen BW; Vang O
Mech Ageing Dev; 2016 Jan; 153():22-9. PubMed ID: 26763146
[TBL] [Abstract][Full Text] [Related]
18. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines.
Herrera VA; Zeindl-Eberhart E; Jung A; Huber RM; Bergner A
Anticancer Res; 2011 Mar; 31(3):849-54. PubMed ID: 21498705
[TBL] [Abstract][Full Text] [Related]
19. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment.
García-Echeverría C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4308-12. PubMed ID: 20561789
[TBL] [Abstract][Full Text] [Related]
20. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
Sankhala K; Giles FJ
Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
